Allan, John

Publications

Sort by

Co-Author Network

Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Academic Article GET IT
Primary Effusion Lymphoma in an HIV-Negative Patient with Chronic Myeloid Leukemia Treated with Dasatinib. 2023 GET IT
Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study. Clinical lymphoma, myeloma & leukemia. 2023 Academic Article GET IT
A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. Leukemia & lymphoma. 2019 Academic Article GET IT
Times cited: 18
Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells. British journal of haematology. 2018 Academic Article GET IT
Times cited: 14
Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22. Leukemia. 2016 Academic Article GET IT
Times cited: 44

Sort by

Co-investigator Network

Zanubrutinib and Venetoclax as Initial Therapy for CLL with Obinutuzumab Consolidation in Patients with Minimal Residual Disease Positivity. awarded by Conquer Cancer Foundation of the American Society of Clinical Oncology Principal Investigator 2022 - 2023

Mechanisms of enhancer regulation in leukemia awarded by National Cancer Institute Co-Investigator 2019 - 2023